File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice

TitleIntranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice
Authors
Qu, DZheng, BYao, XGuan, YYuan, ZHZhong, NSLu, LWXie, JPWen, YM
KeywordsInactivated vaccine
Intranasal immunization
SARS-CoV
Issue Date2005
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2005, v. 23 n. 7, p. 924-931 How to Cite?
DOI: http://dx.doi.org/10.1016/j.vaccine.2004.07.031
AbstractSARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID 5.0 of the live virus 10 3.6 to 10 4.6 times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with CpG, or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50, specific IgA was detected in tracheal-lung wash fluid by immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in intranasal immunization with inactivated. SARS-CoV is discussed. © 2004 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/79061
ISSN
0264-410X
2021 Impact Factor: 4.169
2020 SCImago Journal Rankings: 1.585
ISI Accession Number ID
WOS:000226326400011
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorQu, Den_HK
dc.contributor.authorZheng, Ben_HK
dc.contributor.authorYao, Xen_HK
dc.contributor.authorGuan, Yen_HK
dc.contributor.authorYuan, ZHen_HK
dc.contributor.authorZhong, NSen_HK
dc.contributor.authorLu, LWen_HK
dc.contributor.authorXie, JPen_HK
dc.contributor.authorWen, YMen_HK
dc.date.accessioned2010-09-06T07:50:07Z-
dc.date.available2010-09-06T07:50:07Z-
dc.date.issued2005en_HK
dc.identifier.citationVaccine, 2005, v. 23 n. 7, p. 924-931en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/79061-
dc.description.abstractSARS-CoV (severe acute respiratory syndrome-associated coronavirus) strain GZ50 was partially purified and inactivated with 1:2000 formaldehyde. In cell culture the inactivated virus blocked the replication of live virus by decreasing the TCID 5.0 of the live virus 10 3.6 to 10 4.6 times. Inactivated GZ50 was used to immunize mice intranasally either alone, or after precipitation with polyethylene glycol (PEG), or with CpG, or CTB as an adjuvant. The titer of serum neutralizing antibodies was up to 1:640. In mice immunized with adjuvants or PEG precipitated GZ50, specific IgA was detected in tracheal-lung wash fluid by immunofluorescence. Though serum antibodies were detected, no anti-SARS-IgA could be detected in mice immunized only with inactivated GZ50. The roles of adjuvants in intranasal immunization with inactivated. SARS-CoV is discussed. © 2004 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.rightsVaccine. Copyright © Elsevier Ltd.en_HK
dc.subjectInactivated vaccineen_HK
dc.subjectIntranasal immunizationen_HK
dc.subjectSARS-CoVen_HK
dc.subject.meshAdministration, Intranasalen_HK
dc.subject.meshAnimalsen_HK
dc.subject.meshAntibodies, Viral - biosynthesis - blooden_HK
dc.subject.meshCercopithecus aethiopsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLung - immunology - metabolismen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiceen_HK
dc.subject.meshMice, Inbred BALB Cen_HK
dc.subject.meshSARS Virus - immunologyen_HK
dc.subject.meshVaccines, Inactivated - administration & dosage - immunologyen_HK
dc.subject.meshVero Cellsen_HK
dc.subject.meshViral Vaccines - administration & dosage - immunologyen_HK
dc.titleIntranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in miceen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=23 &issue=7&spage=924&epage=931&date=2005&atitle=Intranasal+immunization+with+inactivated+SARS-CoV+(SARS-associated+coronavirus)+induced+local+and+serum+antibodies+in+miceen_HK
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hken_HK
dc.identifier.emailGuan, Y: yguan@hkucc.hku.hken_HK
dc.identifier.emailLu, LW: liweilu@hkucc.hku.hken_HK
dc.identifier.authorityZheng, B=rp00353en_HK
dc.identifier.authorityGuan, Y=rp00397en_HK
dc.identifier.authorityLu, LW=rp00477en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2004.07.031en_HK
dc.identifier.pmid15603894-
dc.identifier.scopuseid_2-s2.0-10444272332en_HK
dc.identifier.hkuros99117en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-10444272332&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue7en_HK
dc.identifier.spage924en_HK
dc.identifier.epage931en_HK
dc.identifier.isiWOS:000226326400011-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridQu, D=7006530448en_HK
dc.identifier.scopusauthoridZheng, B=7201780588en_HK
dc.identifier.scopusauthoridYao, X=34973484500en_HK
dc.identifier.scopusauthoridGuan, Y=7202924055en_HK
dc.identifier.scopusauthoridYuan, ZH=7401476740en_HK
dc.identifier.scopusauthoridZhong, NS=7102137996en_HK
dc.identifier.scopusauthoridLu, LW=7403963552en_HK
dc.identifier.scopusauthoridXie, JP=7402994715en_HK
dc.identifier.scopusauthoridWen, YM=7401776949en_HK
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats